Moderna Walks Away from Potential $3B Gene Editing Deal with Metagenomi
Pictured: Entrance to Moderna's office in Massachusetts/iStock, hapabapa Moderna has backed out of its gene editing deal with Metagenomi, handing back full global rights to the primary hyperoxaluria type 1 program and other related technologies, …